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The uric acid alteration in human beings causes major health problem due to its pivotal role in the etiology of many 
systemic diseases. The purine metabolism enzyme activities have a significant role in the process of elevated uric acid in 
diabetes mellitus. Hence, a study has been undertaken to understand the alteration of these enzyme activities in diabetic 
condition with an attempt to establish the possible cause for uric acid elevation. Alloxan was administered (150 mg/kg; i.p.) 
to induce diabetes in rats. Thirty days after alloxan induced diabetes, the enzyme activities were assessed in both plasma and 
liver tissues. The enzyme activities such as 5-nucleotidase (5-NT), adenosine deaminase (ADA), xanthine oxidase (XO) in 
the plasma and liver tissues were assayed by spectrometric technique and uric acid levels were also measured by Caraway 
procedure. A significant (P< 0.001) increase in 5-NT, ADA and XO enzyme activities in plasma and liver tissue with a 
concomitant increase (P< 0.001) in uric acid levels was observed in diabetic group. The uric acid and the activities of 
enzymes did not change significantly in control group. From the present study, it can be concluded that an increase in uric 
acid levels noticed in diabetic condition may be due to increased catabolism of purines as evidenced by increased activities 
of 5-NT, ADA and XO enzymes. 
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Diabetes mellitus comprises a group of metabolic 
disorders that are characterized by chronic 
hyperglycemia associated with disturbances of 
carbohydrate, fat and protein metabolism due to 
defects in insulin secretion, decreased insulin 
sensitivity, or both
1,2
. The incidence of diabetes is 
gradually increasing mainly due to changes in eating 
habits and lifestyle which alter the functions of most 
of the organ systems
 
such as cardiovascular, neuronal, 
excretory and reproductive systems
3
. Based on 2017 
report, 451 million people are associated with 
diabetes worldwide and 90% of them have type 2 
diabetes. It is expected to rise upto 592 million by 
2035
1
. Alloxan induced diabetic model is well used to 
understand the complications as well as to test the 
therapeutic drugs
4
. 
The purine bases (both endogenous and exogenous) 
are constituents of nucleotides, which undergo a 
continuous process of synthesis, interconversion and 
breakdown. The catabolic process leads to the free 
purine bases, adenine and guanine which are 
enzymatically oxidized to form uric acid (UA)  
(Fig. 1). The absence, deficiency or exacerbated 
activities of the enzymes involved result in various 
inherited metabolic disorders that are characterized by 
abnormal concentrations of UA, purines and/or other 
metabolites in cells and body fluids
5
. 
Serum UA levels are an important risk factor of 
disease progression for a number of diseases, 
including those related to lifestyle. The metabolic 
syndrome and type 2 diabetes mellitus are two 
specific life style-related diseases, which often lead  
to common pathological complication
6
. By its 
antioxidant property serum uric acid exerts  
neuro-protective effects against Alzheimer's disease 
caused by oxidative injuries, and lowers the 
progression risk from impaired cognitive function to 
dementia
7,8
. Considerable evidence in the recent past 
has shown elevated UA levels in many diabetic 
subjects
9
. However, no studies have examined  
the association between purine metabolism enzymes 
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(5-NT, ADA and XO) activities and the risk of 
developing hyperuricemia in diabetes.  
Enzyme 5-nucleotidase (NT) catalyzes the 
conversion of nucleoside monophosphates or 
deoxynucleoside monophosphates into nucleosides 
and deoxynucleosides by releasing more inorganic 
phosphates via hydrolysis of a phosphodiester bond. 
This enzyme, together with nucleotide kinase, 
regulates the pool of the nucleotides in cells
10
. 
Adenosine deaminase (ADA) is an important 
cytosolic enzyme involved in the metabolism of 
purine nucleosides; it catalyzes the irreversible 
hydrolytic deamination of both adenosine and  
2-deoxyadenosine to inosine and 2-deoxyinosine, 
respectively
11
. Xanthine oxidase (XO) is an  
iron-sulfur molybdenum-containing cytosolic enzyme 
that plays a role in nucleotide metabolism. It is 
involved in the sequential oxidation of hypoxanthine 
to xanthine, and xanthine to uric acid and hydrogen 
peroxide in the purine catabolic pathway. XO is 
housekeeping and the rate-limiting enzyme in purine 
catabolism
12
 (Fig. 1).  
Some reports indicate that uric acid elevation is 
related to diabetic complications, whereas a few 
claimed that uric acid elevation is also seen in 
prediabetic condition
13
. The reason for this elevation 
of uric acid and a possible role of insulin in this 
regard are obscure and the data is inconclusive and 
controversial. Hence, this study explored the link 
between the alteration in 5-NT, ADA and XO 
enzyme activities and uric acid levels in plasma and 
liver tissues of diabetic rats. 
 
Materials and Methods 
 
Chemicals  
Alloxan monohydrate was procured from Sigma 
Aldrich chemicals (St. Louis, U.S.A). Adenosine 
deaminase and xanthine oxidase were purchased from 
Thermo Fisher (USA).Other chemicals and solvents 
were of Analytical Reagent (AR) grade, purchased 
from Randox Laboratories (UK). 
 
Animals 
Randomly selected healthy male Albino Wistar rats 
weighing 150-180 g were housed in polycarbonate 
cages in normal day-night cycle and temperature 
maintained at 22±2C. The rats were fed with 
commercial rat feed (Amruth Rat Feed, supplied by 
Pranav Agro Industries, Pune, India) and had free 
access to water ad libitum. The animal experiments 
were conducted as per CPCSEA guidelines and this 
work was approved by Institutional Animal Ethics 
Committee (IAEC) of Basaveshwara Medical  
College and Hospital, Chitradurga (BMCH/IAEC/05 
Biochem/2015, dated 04.06.2015). 
 
Experimental design 
For the experimental work, the animals were divided 
into 2 groups consisting of 6 animals in each group. 
 
 
Fig. 1 — Purine nucleotide catabolic pathway 
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The rats which received normal saline (1 mL/kg b.w) 
orally were served as normal control; For another 
group of rats, diabetes was induced by using freshly 
prepared solution of Alloxan monohydrate dissolved in 
normal saline to 18 h fasted rats as a single dose  
(150 mg/kg; intraperitonally-i.p.). Animals were given 
5-10% glucose to drink after alloxan injection to 
prevent hypoglycaemia. Hyperglycemia was confirmed 
by confirming elevated glucose levels in blood 
determined at 48 h after injection and the animals 
tested for glucose positive for 3 consecutive days. Rats  
with blood-glucose levels above 250 mg/dL were 
considered diabetic and selected for the study
14
. 
After a stipulated period of 30 days, the animals 
were anesthetized using isoflurane, and blood was 
collected in plain and heparinized tubes by retro-
orbital puncture. The rats were weighed and sacrificed 
by injecting with sodium pentobarbitone immediately 
after sacrifice for assays. Blood plasma was separated 
by centrifugation (1700 × g, 15 min, 8°C) and 
immediately stored at −80°C. Liver tissue was 
aseptically removed and washed with saline and tissue 
homogenate was prepared using phosphate-buffered 
saline (PBS), pH 7.4 and maintained at −4C until 
further assay. The plasma and liver tissues were then 
employed for the estimation of UA and for the assay 
of 5-NT, ADA and XO activities.  
 
Estimation of uric acid 
Uric acid was estimated according to the method of 
Caraway
15
. To 5.4 mL of diluted tungstic acid, 0.6 mL 
of plasma sample was added, mixed well and 
centrifuged. To the test tubes 3.0 mL of supernatant,  
0.6 mL of sodium carbonate and 0.6 mL of 
phosphotungstic acid reagent were added, mixed and 
placed in a 25C water bath for 10 min. The blue colour 
developed was read at 660 nm. The uric acid levels were 
expressed as mg/dL. The liver tissue (100 mg) was 
homogenized in 100 mM Tri-HCl buffer (pH 7.4), with 
ten times the volume of tissue using a tissue homogenizer. 
A part of the homogenate was used to measure protein 
concentration and uric acid was analysed in cytosolic 
fraction (20 µg of protein) by phosphotungstic acid 
method and expressed as µg/mg protein. 
 
Estimation of xanthine oxidase  
The activity of XO was assayed by the method of 
Hashimoto et al.
16
. The liver tissue was homogenized 
in 9 volumes of ice-cold 0.25M sucrose. The sonicated 
homogenate was centrifuged at 4°C (10000 g for  
20 min), and the supernatant was dialyzed against  
100 volumes of the same solution at 4°C for 24 h, and 
assessed for protein content by Bradford method.  
3.0 mL of incubation mixture included 150 µM 
phosphate buffer, 0.2 µM xanthine, 0.3 µM potassium 
oxonate and 10 µg of protein. The mixtures were 
incubated at 30°C for 30 min, added with 0.1 mL of 
100% of TCA (trichloro acetic acid), mixed well, then 
centrifuged at 10000 × g for 15 min and supernatant was 
analysed for xanthine oxidase activity. The test samples 
and standards were read against the blank at 292 nm. 
One unit (U) of this enzyme is defined as the amount of 
enzyme forming 1 µM uric acid/min/mg protein. The 
xanthine oxidase activity in plasma was assayed with an 
assay kit (Biolab kits) and expressed as mU/mL. 
 
Assay of adenosine deaminase  
The activity of ADA enzyme was measured using 
adenosine substrate based on the colorimetric method 
described by Giusti and Galanti
17
. The absorbance of 
blue-colored complex formed at the end of reaction 
was measured using semi automated chemistry 
analyzer at 620 nm. 
 
Assay of 5-nucleotidase  
The enzymatic assay was carried out in a reaction 
medium containing 10 mM MgCl2, 100 mM NaCl,  
5 mM KCl, 6 mM glucose and 50 mM Tris–HCl buffer, 
pH 7.4, at a final volume of 200 µL as described by 
Lunkes
18
. Twenty microliters of the enzyme preparation 
(8-10 μg of protein) was added to the reaction mixture 
and the pre-incubation proceeded for 10 min at 37°C. 
The reaction was initiated by the addition of AMP 
(Adenosine monophosphate) at a final concentration of 
2.0 mM, and the time of incubation was 60 min. The 
reaction was stopped by the addition of 200 µL 10% 
TCA (final concentration 5%). The results are expressed 
as nm Pi released/ min/mg protein. 
 
Statistical analysis 
Data obtained from the control and experimental 
rats (n=6/group) are expressed as Mean ± SEM. For 
statistical analysis, data were subjected to Student’s  
t-test. The Dunnett post hoc analysis was  
performed to compare between the groups. A level of 
P< 0.05 was taken as significant. The statistical 
analysis was done using the SPSS statistical package 
(version 22.0). 
 
Results 
Experimental data demonstrating the ADA activity in 
the plasma and liver of diabetic subjects are shown in 
(Fig. 2). These findings indicate that plasma and liver 
ADA activity in the diabetic group was significantly 
higher (P< 0.001) in comparison with control group.  
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We observed that there was significant (P< 0.001) 
increase in xanthine oxidase and 5-nucleotidase 
activities in liver and plasma of diabetic rats when 
compared to the control group (Figs. 3A & B and 4). 
 
 
Fig. 5 — This graph depicts the plasma and liver uric acid levels 
in normal control and diabetic rats. Results are expressed as  
Mean ± SD (n=6); ***P< 0.001 as compared to normal control group 
 
The results of the uric acid level in liver and 
plasma are shown in (Fig. 5). Diabetic rats showed a 
significant (P< 0.001) increase in uric acid levels than 
normal control group. The uric acid elevation is very 
well correlated with hyperglycemic condition. 
 
Discussion 
Uric acid (UA) is a purine derivative formed by the 
breakdown of purines and by direct synthesis from  
5-phosphoribosyl pyrophosphate and glutamine. 
Elevated serum levels of UA have been shown to play 
an important role in many disease states including 
gout and articular degenerative disorders as well as 
vascular inflammation and atherosclerosis
19
. In 
Alzheimer’s disease serum UA level has been 
significantly reduced, which support oxidative injuries 
could play an important role in the pathogenesis  
of AD
20
. Raised levels of uric acid in serum  
has been proposed to induce insulin-resistant state  
in the body at various conditions
21
. 
Uric acid formation and excretion are driven by 
several enzymatic pathways which occur via different 
genetically-defined isoforms, and are highly regulated 
by pathophysiological determinants including metabolic 
products and free radical species. Xanthine oxidase 
reductase represents the most relevant pathway 
involved in UA overproduction and offers significant 
perspectives for a better pharmacological approach 
for treating hyperuricemia-related vascular and non-
vascular disorders in diabetes mellitus condition
22
.  
In this study, we investigated the connection between 
elevated UA levels in liver and plasma and the 
alterations in nucleoside metabolic enzymes. 
ADA, 5′NT and XO are enzymes of purine 
nucleoside metabolism that play an important role in 
 
 
Fig. 2 — This graph depicts the plasma and liver ADA activities 
in experimental rats. Results are expressed as Mean ± SEM (n=6);  
*** P< 0.001 significantly different as compared to normal control 
group 
 
 
 
Fig. 3 — Depicts the xanthine oxidase activity in (A) liver tissue  
and; (B) plasma of normal control and diabetic rats. Results were 
expressed as Mean ± SEM (n=6) animals. *** P< 0.001 
statistically significant as compared with normal control rats 
 
 
 
Fig. 4 — This graph depicts the 5-nucleotidase activities in liver 
tissue and plasma of normal control and diabetic rats. Results are 
expressed as Mean ± SD (n=6); *** P< 0.001 statistically 
significant as compared to normal control group 
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the regulation of adenosine levels
23
. Adenosine 
deaminase is one of the key enzymes of purine 
nucleoside metabolism, participating in the conversion 
of adenosine to inosine and 2-deoxyadenosine. These 
enzymes are able to regulate the extracellular 
concentrations of adenine nucleotides and nucleosides 
and play an important role in the maintenance of 
normal hemostasis and thrombogenesis
24
. Corroborating 
with the current results, a significant elevation of ADA 
activity in the tissues of diabetic rats induced with 
streptozotocin was noted by many researchers. 
Previous studies have proved that the insulin is 
involved in the regulation of ADA activity in 
diabetes
25
. However, it is not clear whether changes in 
ADA activity are the cause or result of altered  
insulin resistance. Increased ADA enzyme activity  
may reflect the decrease in adenosine circulation, 
leading to the declining of sensitivity by insulin and 
consequently the increase of glucose
26
. 
The enzyme ecto-5-Nucleotidase is located in the 
tissues promoting the hydrolysis of AMP to its 
nucleoside, adenosine, in the extracellular medium
27
. 
Many studies reported that 5NT expression was 60% 
higher in diabetes mellitus than the control, which  
is probably related with the thromboregulation 
process
28
. Significantly elevated 5-Nucleotidase 
activity was also reported in the hypertensive (60%) 
and type 2 diabetic/hypertensive (53%) groups  
(P< 0.01) and compared with control and type  
2 diabetic group
18
. This evidence supports the 
findings of present research study. 
Experimental and clinical studies have proven that 
hyperuricemia is not only associated with gout but also 
diabetes mellitus. Uric acid is the reduced form of 
xanthine oxidoreductase (XOR) (known as xanthine 
oxidase (XO), and xanthine dehydrogenase (XDH), 
respectively) from hypoxanthine and xanthine which is 
generated via the purine degradation pathway
29
. Most 
of the xanthine oxidase enzyme is derived from the 
liver throughout the body in humans, during liver 
inflammation; XDH is released into the circulation 
and is subsequently converted into xanthine oxidase 
(XO) by proteases in the peripheral vasculature. 
Importantly, XO locally produces a considerable 
amount of reactive oxygen species (ROS), such as 
H2O2 and O2
30
. In this context, we analysed the higher 
levels of uric acid with higher activity of XO in 
plasma and also in liver tissues, thereby uncovering 
hidden risks for the altered insulin action in type 2 
diabetes mellitus. 
Conclusion 
In the present study, the elevation of adenosine 
deaminase, xanthine oxidase and 5-nucleotidase 
activity was significantly correlated with insulin 
secretion and liver dysfunction. The changes in these 
enzyme activities were associated with high levels of 
uric acid in liver tissue and plasma of diabetic rats.  
An extended prospective study is required to establish 
the purine catabolism alterations and correlation  
with diabetes mellitus. 
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